News
The Board of Directors of The AES Corporation (NYSE: AES) declared a quarterly common stock dividend of $0.17595 per share ...
Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback